NovoCure (NVCR) Stock Surges on Pancreatic Cancer Treatment Approval

TLDR NovoCure (NVCR) stock gained 29.33% in pre-market Thursday after FDA approved Optune Pax for locally advanced pancreatic cancer treatment. Regulatory clearance came one quarter earlier than expected, originally anticipated in Q2 2026. PANOVA-3 Phase 3 trial with 571 patients met primary endpoint, showing improved median overall survival rates. H.C. Wainwright upgraded price target from [...]

The post NovoCure (NVCR) Stock Surges on Pancreatic Cancer Treatment Approval appeared first on Blockonomi.